UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

STEADYMED LTD.
Petitioner

v.

UNITED THERAPEUTICS CORPORATION Patent Owner

U.S. Patent No. 8,497,393
Issue Date: Jul. 30, 2013
Title: PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®

Case IPR2016-00006

Patent Owner's Exhibit List

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450



Ex#	Exhibit Description
2001	November 19, 2015 Conference Call Before the Panel
2002	Remodulin Label
2003	FDA Approval Letter
2004	Process Validation Report: (Protocol No.: "VAL 00131")
2005	Process Optimization Report
2006	UTC Letter of January 2009 to FDA
2007	U.S. Patent No. 8,242,305; the '305 patent;
2008	U.S. Provisional Patent Application No. 61/014,232
2009	U.S. Patent No. 8,748,657; the '657 patent
2010	The '657 patent prosecution history
2011	Zumdahl, Chemistry, pp. A25, A36 (1986)
2012	Brown, et al., Chemistry: The Central Science, pp. G-2, G-10 (9th ed.
	2003)
2013	Trial testimony of Dr. Williams and Dr. Aristoff
2014	Suchocki, et al., Conceptual Chemistry, p. G-6 (2001)
2015	U.S. Patent No. 4,668,814; the '814 patent



IPR2016-00006 Patent 8,497,393

2016	UTC Form 10K 2014 Annual Report

Respectfully submitted,

Date: Jan. 14, 2016

/Stephen B. Maebius/ Stephen B. Maebius Registration No. 35,264 Counsel for Patent Owner



CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing Patent Owner's Exhibit List and a copy of each listed exhibit except for Exhibit Nos. 2003-2006 (which are filed under seal) were served on counsel of record for the Petitioner on Jan. 14, 2016 by delivering a copy via email to Stuart Pollack and Lisa Haile (the counsel of record for the Petitioner) at the following address: Steadymed-IPR@dlapiper.com.

Date: Jan. 14, 2016 /Ste

/Stephen B. Maebius/
Stephen B. Maebius
Registration No. 35,264
Counsel for Patent Owner

